Biogeneosp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Biogeneo develops highly concentrated cosmetics and formulas for skin regeneration and rejuvenation, intended for professional clinics and the fields of dermatology and medicine. Its portfolio includes the MediRegene INTENSE Clinical PRO line, developed by scientists and professionals with regenerative and anti-aging active ingredients; the products are tested for safety and quality and developed according to sustainable business principles.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 2 of 3 financial statements were filed late (the longest delay 318 days for 2024).
- 2025not filed
- 202429/05/2026
- 202301/09/2024
- 202215/07/2023
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Offer
- Skin-repair cosmetics
- Anti-aging cosmetics
- Skin care preparations
Website technology
- Website
- WordPress
- Elementor
Authorized Representatives
Manner of representation
In the case of a one-person management board, the company is represented independently by the only member of the management board. In the case of a two-member management board, the President of the Management Board is entitled to represent the company independently, and the other member of the management board is entitled to represent the company jointly with the President of the Management Board or jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Violetta Zarzyckaage 58 | 182 | $2,458.13 | 91% |
Others | 18 | $243.11 | 9% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2022-07-01 to 2025-12-01.
Reason for removal: Art. 96 ust. 9 pkt 2 (contact with the taxpayer or their representative is impossible despite documented attempts)
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 28, 2022 | Aid for SME access to finance — aid for start-ups | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| SKIN Lab Internationalsp. z o.o. | $295,930.15 | skinlab.pl | ||
| MultiqureS.A. | $284,781.52 | purebiologics.com | ||
| Medpolmatsp. z o.o. | $257,948.21 | medpolmat.pl | ||
| FcbiotechS.A. | $246,877.92 | fcbiotech.pl | ||
| Countess Laboratoriessp. z o.o. | $164,970.29 | countess.pl | ||
| Kolgenisp. z o.o. | $133,912.89 | kolgeni.pl | ||
| Microbe Plussp. z o.o. | $104,197.26 | microbe-plus.com | ||
| Biomatgelsp. z o.o. | $35,530.14 | biomatgel.pl | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-10-27 | Address change (Kowalska 5/203, 20-115, Lublin → Aleja Jana Pawła Ii 27, 00-867, Warszawa) | |
| 2026-05-20 | Address change (Ul. Frezerów 3, 20-209, Lublin → Kowalska 5/203, 20-115, Lublin) | |
| 2022-10-21 | Share capital increase (5,000.00 PLN → 10,000.00 PLN) | |
| 2022-05-06 | Entered in the register |
FAQ
Last updated: 2026-10-28